VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE
· Real-Time Price · USD
1.37
0.03 (2.24%)
At close: May 02, 2025, 3:59 PM
1.36
-0.73%
After-hours: May 02, 2025, 05:48 PM EDT
2.24% (1D)
| Bid | 1.34 |
| Market Cap | 20.84M |
| Revenue (ttm) | 501K |
| Net Income (ttm) | -39.81M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -1.47 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 1.5 |
| Volume | 112,802 |
| Avg. Volume (20D) | 159,206 |
| Open | 1.35 |
| Previous Close | 1.34 |
| Day's Range | 1.34 - 1.39 |
| 52-Week Range | 1.27 - 4.30 |
| Beta | 1.37 |
About VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 13
Stock Exchange NASDAQ
Ticker Symbol VYNE
Website https://www.vynetherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VYNE stock is "Buy." The 12-month stock price forecast is $6.25, which is an increase of 356.20% from the latest price.
Stock ForecastsNext Earnings Release
VYNE Therapeutics Inc. is scheduled to release its earnings on May 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-23.94%
VYNE Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
